0105 areas
Amylin receptor pharmacology
ORP-CAG is investigated as a tool to probe AMYR1-3 receptor biology and understand downstream signaling cascades in metabolic tissues.
Optimum ReGen Peptides21+
Research use only
All research products on this site, including all peptides, are sold strictly for laboratory and research use only, not for human or animal consumption, diagnostic, or therapeutic use. Our tallow skincare products are topical cosmetics. You must be 21 or older to enter.
Third-party testedHPLC + MSMedford, OR
By entering you confirm you are 21+ and accept these products are for research use only. See our Terms and Disclaimer.
ORP‑CAG
For laboratory research. Sold in 5mg and 50mg kit sizes.
$41.40
$6031% off
In stock2-Day Priority Air anywhere in the US
Choose your size
Savings per mg compared with the 5mg size.
1
Secure checkout2-Day Priority Air
Complete the order
Frequently bought together
Supplies and compounds researchers add to this order
Finding add-ons…
Shipping & returns
- 2-Day Priority Air: $13 flat anywhere in the US, or pick up in Medford.
- Tracking is emailed the moment your order ships.
- Research compounds are final sale; see the refund policy.
Lab sheet
ORP-CAG details
Identity, purity and handling data for this compound, in one place. Tap an identifier to copy it.
Certificate of analysis
Not published yet
A third-party certificate for ORP-CAG is not published here yet. If your work needs one, ask us before ordering and we will tell you what testing is available for the current lot.
Ask about a certificateMolar Mass
Approx. 4296 Da (conjugated form)
CAS Number
2381272-26-8
Form
Lyophilized powder
Full data sheet+
- Purity
- See the available batch report for the tested sample's purity. Confirm the product and lot before ordering.
For research use only. Not for human consumption.
Overview
About ORP-CAG
ORP-CAG is a long-acting amylin analogue developed for investigation in metabolic research. Amylin is a pancreatic peptide co-secreted with insulin that plays roles in postprandial glucose regulation, gastric emptying, and satiety signaling. ORP-CAG was engineered with fatty acid conjugation to extend its half-life relative to native amylin.
Read moreShow less
Research interest in ORP-CAG centers on its activity at amylin receptors (AMYR), calcitonin receptors, and CGRP receptor subtypes. Preclinical models have investigated its effects on food intake regulation, body weight trajectories, and glycemic parameters when administered alone or in combination with GLP-1 receptor agonists.
As a research compound, ORP-CAG is studied to better understand amylin receptor pharmacology and the additive or synergistic interactions possible when dual amylin/GLP-1 receptor pathways are engaged simultaneously. It is intended exclusively for laboratory research use and not for human or veterinary therapeutic application.
Research context
What ORP-CAG is researched for
The areas where this compound appears in the published research literature.
Methodology
How ORP-CAG is studied
01Method 1In preclinical models, ORP-CAG's long-acting pharmacokinetic profile is used to study sustained amylin receptor occupancy.+
In preclinical models, ORP-CAG's long-acting pharmacokinetic profile is used to study sustained amylin receptor occupancy. Researchers measure outcomes including food intake, body weight, fasting glucose, and insulin sensitivity across study durations.
02Method 2Combination study designs pair ORP-CAG with ORP-1(SM) or other GLP-1 receptor agonists to evaluate whether dual amylin/GLP-1 receptor engagement produces outcomes distinct from either mechanism alone.+
Combination study designs pair ORP-CAG with ORP-1(SM) or other GLP-1 receptor agonists to evaluate whether dual amylin/GLP-1 receptor engagement produces outcomes distinct from either mechanism alone. Such designs help researchers model the pharmacodynamics of multi-target metabolic interventions.
03Method 3In vitro receptor binding assays and cAMP accumulation studies are used to characterize ORP-CAG's affinity and activity at AMYR subtypes relative to native…+
In vitro receptor binding assays and cAMP accumulation studies are used to characterize ORP-CAG's affinity and activity at AMYR subtypes relative to native amylin and other analogues, providing mechanistic context for the in vivo observations.
Storage protocols
ORP-CAG storage and handling
Full handling protocol+
Store lyophilized ORP-CAG at -20 C or below, protected from light and moisture. Once reconstituted in an appropriate sterile diluent, aliquot and store at -80 C for longer-term stability or at 4 C for short-term use within the validated stability window documented in your laboratory protocol. Minimize freeze-thaw cycles. All storage and handling should comply with institutional biosafety and chemical hygiene guidelines.
Ordering & shipping
Buy ORP-CAG online
ORP-CAG for sale from Optimum ReGen Peptides, a US research-peptide company with a storefront in Medford, Oregon. It is in stock, priced from $60. Every order ships 2-Day Priority Air, a $13 flat rate anywhere in the US, with tracking, or can be picked up at the store.
ORP-CAG is supplied as lyophilized powder, for laboratory and research use only, not for human consumption.
FAQ
ORP-CAG FAQ
What is ORP-CAG's receptor selectivity profile?
ORP-CAG acts primarily at amylin receptors (AMYR1-3), which are heterodimeric complexes of the calcitonin receptor with receptor activity-modifying proteins (RAMPs). It also has measurable activity at calcitonin receptors, which is characteristic of amylin analogues.
How does the fatty acid conjugation affect ORP-CAG's research properties?
Fatty acid conjugation promotes albumin binding in circulation, extending the half-life from minutes (native amylin) to approximately seven days. This allows researchers to study sustained amylin receptor engagement in preclinical models.
What models are used to study ORP-CAG in preclinical research?
Diet-induced obesity (DIO) mouse and rat models are commonly employed. These allow researchers to observe metabolic responses to amylin receptor agonism in a context of existing metabolic dysregulation.
Has ORP-CAG been studied in combination with other compounds?
Yes, a co-formulation with ORP-1(SM) (known as CagriSema) has been evaluated in clinical research settings. Preclinical studies preceded this work and demonstrated additive effects on body weight-related outcomes in animal models.
What is the research status of ORP-CAG?
As of the available research literature, ORP-CAG has progressed through multiple phases of clinical investigation for metabolic conditions. It remains a research compound here and is not approved for therapeutic use in any jurisdiction.
More compounds
Related research compounds
Research library